We are live on ! Find out more
BB

BB Biotech Portfolio holdings

AUM $3.98B
1-Year Est. Return 15.47%
This Fund
S&P 500
This Quarter Est. Return
+31.41%
1 Year Est. Return
+15.47%
3 Year Est. Return
+121.5%
5 Year Est. Return
+265.65%
10 Year Est. Return
–
AUM
$3.98B
AUM Growth
+$856M
Cap. Flow
+$11.5M
Cap. Flow %
0.29%
Top 10 Hldgs %
64.68%
Holding
36
New
2
Increased
14
Reduced
6
Closed
1

Top Buys

1
CRSP icon
CRISPR Therapeutics
CRSP
+$28M
2
NKTR icon
Nektar Therapeutics
NKTR
+$25.3M
3
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$17.9M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$17.2M
5
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$13.3M

Top Sells

1
IONS icon
Ionis Pharmaceuticals
IONS
+$65.6M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$25.5M
3
INCY icon
Incyte
INCY
+$15.3M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$13M
5
GILD icon
Gilead Sciences
GILD
+$12.6M

Sector Composition

1 Healthcare 96.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALDR
26
DELISTED
Alder Biopharmaceuticals
ALDR
$37.8M 0.95%
2,766,008
– –
CRSP icon
27
CRISPR Therapeutics
CRSP
$4.71B
$28.9M 0.73%
+810,462
New +$28M
SRRK icon
28
Scholar Rock
SRRK
$6.33B
$27.8M 0.7%
1,476,839
+196,861
+15% +$3.47M
ITCI
29
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$26.8M 0.67%
2,200,000
– –
SGMO
30
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$25.3M 0.64%
2,650,000
+1,300,000
+96% +$13.3M
KZR
31
DELISTED
Kezar Life Sciences
KZR
$21.7M 0.54%
122,050
+40,207
+49% +$7.92M
GTHX
32
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$11.2M 0.28%
671,925
– –
CDTX
33
DELISTED
Cidara Therapeutics
CDTX
$6.08M 0.15%
114,764
– –
NVAX icon
34
Novavax
NVAX
$1.35B
$4.59M 0.12%
416,500
– –
QTTB icon
35
Q32 Bio
QTTB
$255M
$2.53M 0.06%
+5,074
New +$2.27M
REGN icon
36
Regeneron Pharmaceuticals
REGN
$70.9B
– –
-68,156
Closed -$25.5M
1
2

Similar funds

SBAM
Santa Barbara Asset Management Los Angeles, California $6.43B AUM 10.99% 1-Year Est. Return
HFS
HL Financial Services Louisville, Kentucky $6.5B AUM 9.56% 1-Year Est. Return
SA
SQ Advisors Naples, Florida $1.32B AUM 10.3% 1-Year Est. Return
WF
WealthTrust Fairport Cleveland, Ohio $1.06B AUM 3.47% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
AB
AT Bancorp Dubuque, Iowa $823M AUM 0.35% 1-Year Est. Return
MFBTD
MB Financial Bank - Trust Department Rosemont, Illinois $816M AUM 5.49% 1-Year Est. Return

BB Biotech's Q1 2019 Portfolio in Review

As of Q1 2019, BB Biotech held 36 positions worth $3.98B, up 27% from $3.12B the previous quarter. Its ten largest holdings account for 65% of the portfolio.

BB Biotech's Q1 2019 filing shows 2 new, 14 increased, 6 reduced and 1 closed positions. Its largest new stake was CRISPR Therapeutics: 810,462 shares worth $28.9M. The largest sale was Ionis Pharmaceuticals, an estimated $65.6M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

  • BB Biotech's largest Q1 2019 buy was CRISPR Therapeutics: 810,462 shares worth $28.9M.
  • BB Biotech added most to Nektar Therapeutics in Q1 2019, an estimated $25.3M increase.
  • BB Biotech's biggest Q1 2019 reduction was Ionis Pharmaceuticals, cutting an estimated $65.6M.
  • BB Biotech fully exited Regeneron Pharmaceuticals in Q1 2019, selling an estimated $25.5M.
  • BB Biotech's ten largest holdings make up 65% of its $3.98B portfolio in Q1 2019.
  • BB Biotech opened 2 new positions and closed 1 in Q1 2019.
  • BB Biotech's portfolio value rose 27% quarter-over-quarter to $3.98B.

Based on BB Biotech's 13F filing for Q1 2019, filed 13 May 2019.